Bleselumab (ASKP 1240), a human anti-CD40 monoclonal antibody (mAb), exhibits high-affinity binding to CD40 (Kd: 0.24 nM) and hinders immune responses by impeding the CD40-CD40L interaction, thereby preventing organ transplant rejection [1].

Bleselumab, at a concentration of 0-1 μg/mL attenuates the proliferation of peripheral blood mononuclear cells (PBMCs) over 48 hours in a dose-dependent manner when induced by soluble CD154 [2].

Bleselumab administered intravenously at dosages ranging from 0.1 to 10 mg/kg suppresses delayed-type hypersensitivity (DTH) reactions in cynomolgus monkeys [2]. At 2 mg/kg, it extends the lifespan of renal allografts in these subjects [3]. Additionally, when combined with Tacrolimus, bleselumab at either 2 or 5 mg/kg demonstrates an increased median survival time (MST) compared to when used alone [3].